Are you Dr. Ryerson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 5 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
# M1087
San Francisco, CA 94143Fax+1 415-476-5712
Summary
- Dr. Christopher Ryerson, MD is a pulmonologist in San Francisco, California.
Clinical Trials
- The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease Start of enrollment: 2010 Feb 01
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Publications & Presentations
PubMed
- 2 citationsImpact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis.Monica L Mullin, Gustavo Fernandez, Daniel-Costin Marinescu, Boyang Zheng, Alyson W Wong
Chest. 2024-06-01 - Characteristics of pulse oximetry and arterial blood gas in patients with fibrotic interstitial lung disease.Mira A Donaldson, Kathryn Donohoe, Deborah Assayag, Celine Durand, Jolene H Fisher
BMJ Open Respiratory Research. 2024-03-13 - 1 citationsCharacteristics and risk factors of interstitial pneumonia with autoimmune features.Sana Vahidy, Jonathan Agyeman, Boyang Zheng, Kathryn Donohoe, Nathan Hambly
Respiratory Medicine. 2024-01-01
Press Mentions
Low BMI, Weight Loss Predict Mortality Risk in ILDJanuary 4th, 2022
What the Health?! Can Feather Duvets Really Cause Lung Disease?November 29th, 2019
Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung DiseaseOctober 7th, 2019- Join now to see all
